β Cell Gαs signaling is critical for physiological and pharmacological enhancement of insulin secretion
Authors:
- Megan E. CapozziMCMegan E. Capozzi
- David BouslovDBDavid Bouslov
- Ashot SargsyanASAshot Sargsyan
- Michelle Y. ChanMCMichelle Y. Chan
- Alex ChenACAlex Chen
- Sarah M. GraySGSarah M. Gray
- Katrina ViloriaKVKatrina Viloria
- Akshay BarejaABAkshay Bareja
- Jonathan D. DourosJDJonathan D. Douros
- Sophie L. LewandowskiSLSophie L. Lewandowski
- Jason C.L. TongJTJason C.L. Tong
- Annie HasibAHAnnie Hasib
Open Access
- 3 June 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (16)
Abstract
The incretin peptides glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors coordinate β cell secretion that is proportional to nutrient intake. This effect permits consistent and restricted glucose excursions across a range of carbohydrate intake. The canonical signaling downstream of ligand-activated incretin receptors involves coupling to Gαs protein and generation of intracellular cAMP. However, recent reports have highlighted the importance of additional signaling nodes engaged by incretin receptors, including other G proteins and β-arrestin proteins. Here, the importance of Gαs signaling was tested in mice with conditional, postdevelopmental β cell deletion of Gnas (encoding Gαs) under physiological and pharmacological conditions. Deletion of Gαs/cAMP signaling induced immediate and profound hyperglycemia that responded minimally to incretin receptor agonists, a sulfonylurea, or bethanechol. While islet area and insulin content were not affected in Gnas βcell–/– , perifusion of isolated islets demonstrated impaired responses to glucose, incretins, acetylcholine, and IBMX In the absence of Gαs, incretin-stimulated insulin secretion was impaired but not absent, with some contribution from Gαq signaling. Collectively, these findings validate a central role for cAMP in mediating incretin signaling, but also demonstrate broad impairment of insulin secretion in the absence of Gαs that causes both fasting hyperglycemia and glucose intolerance.Keywords
Funding Information
- National Institutes of Health (DK123075, DK125353, DK046492)
This publication has 69 references indexed in Scilit:
- Body Mass Index Differences in Pseudohypoparathyroidism Type 1aVersusPseudopseudohypoparathyroidism May Implicate Paternal Imprinting of Gαs in the Development of Human ObesityThe Journal of Clinical Endocrinology & Metabolism, 2007
- Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gsα deficiencyJournal of Clinical Investigation, 2005
- A Novel Gαq/11-selective InhibitorJournal of Biological Chemistry, 2004
- Tissue-specific imprinting of the G protein Gs is associated with tissue-specific differences in histone methylationHuman Molecular Genetics, 2004
- Growth Hormone Deficiency in Pseudohypoparathyroidism Type 1a: Another Manifestation of Multihormone ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2003
- Insulin granule dynamics in pancreatic beta cellsDiabetologia, 2003
- Beta cell failure: causes and consequences.2001
- Reduced incretin effect in Type 2 (non-insulin-dependent) diabetesDiabetologia, 1986
- Islet cell analysis and purification by light scatter and autofluorescenceBiochemical and Biophysical Research Communications, 1982
- A method for the purification of single A, B and D cells and for the isolation of coupled cells from isolated rat isletsDiabetologia, 1981